Article
Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
International journal of oncology - 1 May 2015
Tang Jie, Guo Fuchun, Du Yang, Liu Xiaoling, Qin Qing, Liu Xiaoke, Yin Tao, Jiang Li, Wang Yongsheng
Abstract excerpt
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR‑TKIs) have shown promising effects against the growth of non-small cell lung cancer (NSCLC) cells harboring EGFR mutations (EGFR‑mts). However, many patients with NSCLC that are accepted for EGFR‑TKI treatment followed by chemotherapy possess an unknown EGFR status including wild-type EGFR (EGFR‑wt). Little is known about the potential effects of...
Topics
- Animals
- Antineoplastic Agents
- Apoptosis
- Blotting, Western
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- ErbB Receptors
- Female
- Flow Cytometry